IPP Bureau
Siegfried expands US footprint with major acquisition of Noramco & Extractas Bioscience
By IPP Bureau - January 29, 2026
Siegfried plans to grow its exclusive synthesis business in the US by optimizing controlled substance capacity at the Wilmington and nearby Pennsville sites
Bausch Health’s RED-C phase 3 trials fall short, company committed to liver disease research
By IPP Bureau - January 29, 2026
The trials, which enrolled over 1,000 patients across 398 sites in 17 countries, showed that the drug was safe and well-tolerated—but ultimately failed to deliver the hoped-for clinical results
Insilico Medicine’s AI-designed Parkinson’s drug cleared for human trials by FDA
By IPP Bureau - January 29, 2026
The upcoming Phase I trial will test the safety, tolerability, and pharmacokinetics of ISM8969 in healthy volunteers and determine the optimal dosing for future studies
CitiusTech & Ventra Health unveil AI-powered revenue game-changer
By IPP Bureau - January 29, 2026
The platform uses cutting-edge AI and automation to tackle the entire revenue cycle
Venus Remedies bags second PLI disbursement for FY25, nears full-year incentive
By IPP Bureau - January 29, 2026
The successive PLI disbursements validate our disciplined execution and sustained commitment to strengthening India’s domestic pharmaceutical manufacturing capabilities
Eyestem moves closer to blindness breakthrough with phase 2 trial green light
By IPP Bureau - January 29, 2026
The early-stage trial demonstrated an excellent safety profile alongside clinically meaningful improvements in visual acuity
Cupid gets certification for HIV & Hepatitis B test kits, paving way for global expansion
By IPP Bureau - January 29, 2026
The newly certified kits are designed for early detection and large-scale screening programs
Sanofi’s Amlitelimab delivers in Phase 3 trials, heads for global filings
By IPP Bureau - January 28, 2026
In the SHORE phase 3 study, amlitelimab, used in combination with topical therapies, met all primary and key secondary endpoints at Week 24
Trelegy Ellipta gets green light in China for adults with uncontrolled asthma
By IPP Bureau - January 28, 2026
The approval expands the drug’s existing COPD indication, making it the only single-inhaler triple therapy (SITT) available for both respiratory conditions in China
Hongene Biotech bags Gates Foundation grant to boost global mRNA vaccine access
By IPP Bureau - January 28, 2026
Hongene will focus on developing and scaling production of key capping reagents—essential components of mRNA therapeutics—emphasizing accessibility, transparency, and global deployment
Eastman & Kolmar Korea join forces to deliver biodegradable beauty breakthroughs
By IPP Bureau - January 28, 2026
The collaboration will center on expanding access to Eastman’s Esmeri technology
Ionis and Otsuka score EU nod for DAWNZERA, offering new hope for rare HAE patients
By IPP Bureau - January 28, 2026
The EU approval of DAWNZERA is an important milestone that reflects our ongoing commitment to bring this innovative medicine to people in need across the globe
Pangea Laboratory teams with Gene Solutions to bring AI-driven cancer tests to US patients
By IPP Bureau - January 28, 2026
Pangea will use its integrated validation platform and regulatory expertise to oversee analytical and clinical validation of Gene Solutions’ multi-omics technologies.
Parse Biosciences unveils integrated immune profiling in Trailmaker Platform
By IPP Bureau - January 28, 2026
The new functionality complements Parse’s existing Evercode immune products
Truvian Health bags FDA clearance for CBC on TruVerus System
By IPP Bureau - January 28, 2026
TruVerus is the only FDA cleared, multi-modal platform capable of delivering comprehensive routine testing from a single lithium heparin sample
